Dopasafe 500 mg Tablets

  • 124 Patients

Dopasafe 500 mg Tablets

Active ingredient
Legal Category
POM: Prescription only medicine.
This information is intended for use by health professionals
1. Name of the medicinal product”DOPASAFE” Tablets 500 mg.

Qualitative and quantitative composition

DOPASAFE Tablets 500 mg, contain methyldopa equivalent to 500 mg anhydrous methyldopa.

Pharmaceutical form

White,film-coated tablets.
DOPASAFE Tablets 500 mg are scored Tablets.

Clinical particulars

4.1 Therapeutic indications
In the treatment of hypertension.
4.2 Posology and method of administration
Use in adults:
Initial dosage: Usually 250 mg two or three times a day, for two days.
Adjustment: Usually adjusted at intervals of not less than two days, until an adequate response is obtained. The maximum recommended daily dosage is 3 g. Many patients experience sedation for two or three days when therapy with 'DOPASAFE’ is started or when the dose is increased. When increasing the dosage, therefore, it may be desirable to increase the evening dose first. Withdrawal of “Dopasafe”is followed by return of hypertension, usually within 48 hours. This is not complicated generally by an overshoot of blood pressure.
Patients with renal impairment:
Methyldopa is largely excreted by the kidney, and patients with impaired renal function may respond to smaller doses.
Other antihypertensives:
Therapy with “DOPASAFE “may be initiated in most patients already on treatment with other antihypertensive agents by terminating these antihypertensive medications gradually, as required. Following such previous antihypertensive therapy,Dopasafe should be limited to an initial dose of not more than 500 mg daily and increased as required at intervals of not less than two days. When methyldopa is given to patients on other antihypertensives the dose of these agents may need to be adjusted to effect a smooth transition. When 500 mg of DOPASAFE is added to 50 mg of hydrochlorothiazide, the two agents may be given together once daily.
Paediatric population: initial dosage is based on 10 mg/kg of bodyweight daily in 2-4 oral doses. The daily dosage is then increased or decreased until an adequate response is achieved. The maximum dosage is 65 mg/kg or 3.0 g daily, whichever is less.
Older people: The initial dose in elderly patients should be kept as low as possible, not exceeding 250 mg daily; an appropriate starting dose in the elderly would be 125 mg b.d. increasing slowly as required, but not to exceed a maximum daily dosage of 2 g. Syncope in older patients may be related to an increased sensitivity and advanced arteriosclerotic vascular disease. This may be avoided by lower doses.
Method of administration.
4.3 Contraindications
“Dopasafe”is contra-indicated in patients with:
• active hepatic disease, such as acute hepatitis and active cirrhosis
• hypersensitivity to the active substance (including hepatic disorders associated with previous methyldopa therapy), or to any of the excipients listed in section 6.1
• depression
• on therapy with monoamine oxidase inhibitors (MAOIs)
• with a catecholamine-secreting tumour such as phaeochromocytoma or paraganglioma
• with porphyria.
4.4 Special warnings and precautions for use
Acquired haemolytic anaemia has occurred rarely; should symptoms suggest anaemia, haemoglobin and/or haematocrit determinations should be made. If anaemia is confirmed, tests should be done for haemolysis. If haemolytic anaemia is present, 'Dopasafe’should be discontinued. Stopping therapy, with or without giving a corticosteroid, has usually brought prompt remission. Rarely, however, deaths have occurred.
Some patients on continued therapy with methyldopa develop a positive Coombs test. From the reports of different investigators, the incidence averages between 10% and 20%. A positive Coombs test rarely develops in the first six months of therapy, and if it has not developed within 12 months, it is unlikely to do so later on continuing therapy. Development is also dose-related, the lowest incidence occurring in patients receiving 1 g or less of methyldopa per day. The test becomes negative usually within weeks or months of stopping methyldopa.
Prior knowledge of a positive Coombs reaction will aid in evaluating a cross-match for transfusion. If a patient with a positive Coombs reaction shows an incompatible minor cross-match, an indirect Coombs test should be performed. If this is negative, transfusion with blood compatible in the major cross-match may be carried out. If positive, the advisability of transfusion should be determined by a haematologist.
Reversible leukopenia, with primary effect on granulocytes has been reported rarely. The granulocyte count returned to normal on discontinuing therapy. Reversible thrombocytopenia has occurred rarely.
Occasionally, fever has occurred within the first three weeks of therapy, sometimes associated with eosinophilia or abnormalities in liver-function tests. Jaundice, with or without fever, may also occur. Its onset is usually within the first two or three months of therapy. In some patients the findings are consistent with those of cholestasis. Rare cases of fatal hepatic necrosis have been reported. Liver biopsy, performed in several patients with liver dysfunction, showed a microscopic focal necrosis compatible with drug hypersensitivity. Liver-function tests and a total and differential white blood-cell count are advisable before therapy and at intervals during the first six weeks to twelve weeks of therapy, or whenever an unexplained fever occurs.
Should fever, abnormality in liver function, or jaundice occur, therapy should be withdrawn. If related to methyldopa, the temperature and abnormalities in liver function will then return to normal. Methyldopa should not be used again in these patients. Methyldopa should be used with caution in patients with a history of previous liver disease or dysfunction.
Patients may require reduced doses of anaesthetics when on methyldopa. If hypotension does occur during anaesthesia, it can usually be controlled by vasopressors. The adrenergic receptors remain sensitive during treatment with methyldopa.
Dialysis removes methyldopa; therefore, hypertension may recur after this procedure.
Rarely, involuntary choreoathetotic movements have been observed during therapy with methyldopa in patients with severe bilateral cerebrovascular disease. Should these movements occur, therapy should be discontinued.
Interference with laboratory tests:
Dopasafe may interfere with the measurement of urinary uric acid by the phosphotungstate method, serum creatinine by the alkaline picrate method, and AST (SGOT) by colorimetric method. Interference with spectrophotometric methods for AST (SGOT) analysis has not been reported.
As methyldopa fluoresces at the same wavelengths as catecholamines, spuriously high amounts of urinary catecholamines may be reported interfering with a diagnosis of catecholamine-secreting tumours such as phaeochromocytoma or paraganglioma.
It is important to recognise this phenomenon before a patient with a possible phaeochromocytoma is subjected to surgery. Methyldopa does not interfere with measurements of VMA (vanillylmandelic acid) by those methods which convert VMA to vanillin. Methyldopa is contraindicated for the treatment of patients with a catecholamine-secreting tumour such as phaeochromocytoma or paraganglioma.
Rarely, when urine is exposed to air after voiding, it may darken because of breakdown of methyldopa or its metabolites.
4.5 Interaction with other medicinal products and other forms of interaction Lithium:
When methyldopa and lithium are given concomitantly the patient should be monitored carefully for symptoms of lithium toxicity.
Other antihypertensive drugs:
When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive action may occur. The progress of patients should be carefully followed to detect side reactions or manifestations of drug idiosyncrasy.
Other classes of drug:
The antihypertensive effect of 'Dopasafe’may be diminished by sympathomimetics, phenothiazines, tricyclic antidepressants and MAOIs (see 4.3 'Contra-indications'). In addition, phenothiazines may have additive hypotensive effects.
Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulphate or ferrous gluconate. This may adversely affect blood pressure control in patients treated with methyldopa.
4.6 Pregnancy and lactation
'Dopasafe’has been used under close medical supervision for the treatment of hypertension during pregnancy. There was no clinical evidence that ‘Dopasafe caused foetal abnormalities or affected the neonate.
Published reports of the use of methyldopa during all trimesters indicate that if this drug is used during pregnancy the possibility of foetal harm appears remote.
Methyldopa crosses the placental barrier and appears in cord blood.
Although no obvious teratogenic effects have been reported, the possibility of foetal injury cannot be excluded and the use of the drug in women who are, or may become pregnant requires that anticipated benefits be weighed against possible risks.
Methyldopa appears in breast milk. The use of the drug in breast-feeding mothers requires that anticipated benefits be weighed against possible risks.
4.7 Effects on ability to drive and use machines
'Aldomet' may cause sedation, usually transient, during the initial period of therapy or whenever the dose is increased. If affected, patients should not carry out activities where alertness is necessary, such as driving a car or operating machinery.
4.8 Undesirable effects
Sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased. If affected, patients should not attempt to drive, or operate machinery. Headache, asthenia or weakness may be noted as early and transient symptoms.
The following convention has been utilised for the classification of frequency: Very common (≥1/10), common (≥1/100 and <1/10"), uncommon (≥1/1000 and <1/100), rare (≥1/10,000 and<1/1000), very rare (< 1/10,000) and not known (cannot be estimated from the available data). System Organ Class
Adverse event term
Infections and infestations
Not known
Blood and lymphatic system disorders
Haemolytic anaemia, bone-marrow failure, leukopenia, granulocytopenia, thrombocytopenia, eosinophilia
Not known
Endocrine disorders
Not known
Psychiatric disorders
Psychic disturbances including nightmares, reversible mild psychoses or depression, decreased libido
Not known
Nervous system disorders
Sedation (usually transient), headache, paraesthesia, Parkinsonism, VIIth nerve paralysis, choreoathetosis, mental impairment, carotid sinus syndrome, dizziness, symptoms of cerebrovascular insufficiency (may be due to lowering of blood pressure)
Not known
Cardiac disorders
Bradycardia, angina pectoris, myocarditis, pericarditis, atrioventricular block
Not known
Vascular disorders
Orthostatic hypotension (decrease daily dosage)
Not known
Respiratory, thoracic and mediastinal disorders
Nasal congestion
Not known
Gastrointestinal disorders
Nausea, vomiting, abdominal distension, constipation, flatulence, diarrhoea, colitis, dry mouth, glossodynia, tongue discolouration, pancreatitis
Not known
Hepatobiliary disorders
Liver disorders including hepatitis, jaundice
Not known
Skin and subcutaneous tissue disorders
Rash (eczema, lichenoid eruption), toxic epidermal necrolysis, angioedema, urticaria
Not known
Musculoskeletal and connective tissue disorders
Lupus-like syndrome, mild arthralgia with or without joint swelling, myalgia
Not known
Reproductive system and breast disorders
Breast enlargement, gynaecomastia, amenorrhoea, lactation disorder, erectile dysfunction, ejaculation failure
Not known
General disorder and administration site conditions
Asthenia, oedema (and weigh gain) usually relieved by use of a diuretic. (Discontinue methyldopa if oedema progresses or signs of heart failure appear). Pyrexia
Not known
Positive Coombs test, positive tests for antinuclear antibody, LE cells, and rheumatoid factor, abnormal liver-function tests, increased blood urea
Not known

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
4.9 Overdose
Acute overdosage may produce acute hypotension with other responses attributable to brain and gastro-intestinal malfunction (excessive sedation, weakness, bradycardia, dizziness, light-headedness, constipation, distension, flatus, diarrhoea, nausea, and vomiting). Management
If ingestion is recent, emesis may be induced or gastric lavage performed. There is no specific antidote. Methyldopa is dialysable. Treatment is symptomatic. Infusions may be helpful to promote urinary excretion. Special attention should be directed towards cardiac rate and output, blood volume, electrolyte balance, paralytic ileus, urinary function and cerebral activity.
Administration of sympathomimetic agents may be indicated. When chronic overdosage is suspected, 'Dopasafe’should be discontinued.

Pharmacological Properties

5.1 Pharmacodynamic properties
Pharmacotherapeutic group: antiadrenergic agents; ATC code C02AB
Mechanism of action
It appears that several mechanisms of action account for the clinically useful effects of methyldopa and the current generally accepted view is that its principal action is on the central nervous system. The antihypertensive effect of methyldopa is probably due to its metabolism to alpha-methylnoradrenaline, which lowers arterial pressure by stimulation of central inhibitory alpha-adrenergic receptors, false neurotransmission, and/or reduction of plasma renin activity. Methyldopa has been shown to cause a net reduction in the tissue concentration of serotonin, dopamine, epinephrine (adrenaline) and norepinephrine (noradrenaline).
5.2 Pharmacokinetic properties
Absorption of oral methyldopa is variable and incomplete.
Bioavailability after oral administration averages 25%.
Peak concentrations in plasma occur at two to three hours, and elimination of the drug is biphasic regardless of the route of administration. Plasma half-life is 1.8 ± 0.2 hours.
Renal excretion accounts for about two thirds of drug clearance from plasma.
5.3 Preclinical safety data
No relevant information.

Pharmaceutical Particulars

6.1 Excipients.
6.2 Incompatibilities
None known.
6.3 Shelf life
6.4 Special precautions for storage
Keep containers well closed and store below 25°C, protected from light.
6.5 Nature and contents of container
10x10 Tablets in a Box.
6.6 Special precautions for disposal and other handling

7. Date of first authorisation/renewal of the authorisation

21st February 1974/Unlimited validity. Asia Pacific Pharmaceuticals Inc. Medical Information Direct Line +91 9419331895 Website. Mail us

ACIMIN-XR Rabeprazole Sodium 20 mg & Demperidone SR 30 mg Capsules

  • 124 Patients


Rabeprazole sodium and domperidone uses include various gastric conditions which leads to gastric reflux or other symptoms like heartburn, gastric ulcers, difficulty swallowing, and persistent cough.


Increased risk of Clostridium difficile-associated diarrhoea (CDAD) and osteoporosis-related fractures. Headache, rash, pruritus, dizziness, fatigue, cough, back or abdominal pain, arthralgia and myalgia, urticaria, dry mouth, photosensitivity, bullous eruption, fever, angioedema, bronchospasm, somnolence, aggression and vertigo, insomnia, reversible confusional states, depression, agitation, hallucination. Increased liver enzyme, hepatitis, jaundice, hepatic encephalopathy. Rarely, candidiasis, paraesthesia, alopecia, muscular weakness, angina, tachycardia, bradycardia, blurred vision, alopecia, stomatitis, increased sweating, taste disturbances, peripheral oedema, malaise, hyponatraemia, hypomagnesaemia, blood disorders (e.g. agranulocytosis, leucopenia and thrombocytopenia), gynaecomastia, impotence and interstitial nephritis. Potentially Fatal: Anaphylaxis, Stevens-Johnson syndrome and toxic epidermal necrolysis

ACIMIN-L Levosulpiride Sr 75 MG+Rabeprazole SODIUM 20 mg Capsules

  • 124 Patients

Composition of Acimin-L

ACIMIN-L contains combination of Levosulpiride and Rabeprazole sodium
Levosulpiride belongs to a group of gut motility enhancing medicines (gastrointestinal prokinetics)
Rabeprazole sodium works by reducing the production of acid in the stomach.

Therapeutic Uses
Warning & Precautions
Directions & For Use
Side Effects
More Information
What is ACIMIN-L used for?
It is used to treat:
Dyspeptic syndrome: from delayed gastric emptying related to organic factors or functional factors
Nausea and vomiting induced by anticancer drugs
GORD (Gastro-oesophageal Reflux Disease)

CONSIVSURE Letrozole 2.5 mg Tablets

  • 124 Patients

Consivsure 2.5 mg Tablets.

Letrozole for Treating Infertility in Women With PCOS
By Nicole Galan, RN Medically reviewed by Anita Sadaty, MD on October 22, 2020
New research is showing that the breast cancer drug known as letrozole (Consivsure) may be a better option than Clomid to improve pregnancy rates in women with PCOS. This is great news for the millions of women who suffer from PCOS, the leading cause of ovulatory infertility in the United States.

Buena Vista Images / Getty Images
Dr. Richard Legro, a reproductive endocrinologist at Penn State Hershey Medical Center presented results from his recent NIH-sponsored trial at the 2012 American Association of Reproductive Medicine (ASRM) conference that showed 25% of women treated with letrozole had a live birth compared to 16.8% of women who took cloned.
Traditionally, Clomid has been the first-line drug of choice to stimulate ovulation in women with PCOS but has a higher rate of multiple pregnancies and increases exposure to estrogen. In comparison, letrozole doesn't raise estrogen-like Clomid, has a lower risk of cardiac abnormalities and has a lower multiple pregnancy rate.
What Is(Consivsure)Letrozole?
Letrozole is an aromatase inhibitor which prevents the conversion of androgen to estrogen. It also improves endometrial thickness and encourages healthy ovarian follicular development. While not approved by the FDA for this use, it has been shown to induce ovulation in women who do not ovulate. For this reason, some infertility specialists are using the drug in women who cannot tolerate or who do not respond well to Clomid.
Letrozole is a drug that is commonly used to treat estrogen-dependent tumors, particularly breast cancer in older, post-menopausal women.
Letrozole comes in 2.5 mg tablets and is taken once a day for five days, usually beginning on day three or day five of your menstrual cycle. You may need monitoring through blood tests and/or ultrasounds to determine when you are approaching ovulation.
Letrozole should be stopped as soon as pregnancy is achieved.
Letrozole for Treating Infertility in Women With PCOS
By Nicole Galan, RN Medically reviewed by Anita Sadaty, MD on October 22, 2020
New research is showing that the breast cancer drug known as letrozole (Consivsure is ) may be a better option than Clomid to improve pregnancy rates in women with PCOS. This is great news for the millions of women who suffer from PCOS, the leading cause of ovulatory infertility in the United States.
Letrozole is a drug that is commonly used to treat estrogen-dependent tumors, particularly breast cancer in older, post-menopausal women.
Consivsure comes in 2.5 mg tablets and is taken once a day for five days, usually beginning on day three or day five of your menstrual cycle. You may need monitoring through blood tests and/or ultrasounds to determine when you are approaching ovulation.
Letrozole should be stopped as soon as pregnancy is achieved.
This medication is incompatible with pregnancy and breastfeeding. However, please understand that you are taking this drug before you become pregnant, so it does not increase your risk of having a child with birth defects.
Side Effects
Overall, letrozole is well tolerated. Side effects may include:
Weight gain
Bone or muscle pain

CONSIVSURE For breast cancer treatment Hormone therapy

  • 124 Patients

Letrozole (Consivsure).
1. What is letrozole?
2. How does letrozole work?
3. Who it’s suitable for
4. Side effects of letrozole
5. When letrozole is given
6. How long will I have to take it?
7. How it’s taken
8. Taking letrozole with other drugs
1. What is Consivsure (letrozole)?.
Letrozole is a drug used to treat breast cancer in women who have gone through the menopause.
You may also hear it calledConsivsure , which is its best-known brand name. There are a number of other brands of letrozole, all of which contain the same dose of the drug.
Men with breast cancer may be given letrozole(Consivsure)
2. How does letrozole work?.
Consivsure works by reducing the amount of oestrogen made in the body.
Some breast cancers are stimulated to grow by the hormone oestrogen. These are known as oestrogen receptor positive or ER+ breast cancers.
Letrozole belongs to a group of drugs called aromatase inhibitors.
Consivsure is Suitable for?.
Letrozole is suitable for women who have been through the menopause and whose breast cancer is oestrogen receptor positive.
Sometimes Consivsure is given alongside a drug called goserelin to women who haven’t yet been through the menopause.
If her cancer is hormone receptor negative, then Consivsure will not be of any benefit.
4. Side effects of letrozole.
Find out more about the side effects of letrozole.
5. When Consivsure is given.
Letrozole is usually given after surgery to reduce the risk of breast cancer coming back or spreading.
If she is having chemotherapy or radiotherapy, specialist will tell her when it’s best to start Consivsure.
Occasionally, letrozole may be used as the first treatment for breast cancer, for example when surgery isn’t appropriate or needs to be delayed. It’s sometimes given before surgery to shrink a larger breast cancer.
Consivsure can also be used to treat breast cancer that has come back (recurrence). It can also be given to treat breast cancer that has spread to another part of the body (secondary breast cancer), when it’s often given alongside another drug.
6. How long will I have to take it?.
This will depend on your individual circumstances, but letrozole is usually taken for five to ten years.
Some people start taking Consivsure after a few years of taking the hormone therapy drug tamoxifen.
If you’re taking letrozole to treat breast cancer that has come back or spread to another part of the body, you’ll usually take it for as long as it’s keeping the cancer under control.
Stopping letrozole.
Your treatment team will tell you when to stop taking Consivsure.You won’t need to stop taking it gradually.
Some people worry about stopping their treatment, but there’s evidence that letrozole continues to reduce the risk of breast cancer coming back for many years after you stop taking it.
However, not taking the drug for the recommended time may increase the risk of your breast cancer coming back. If you’re thinking about stopping taking letrozole for any reason, talk to your specialist first. Sometimes it may be possible to change to another hormone drug.
Hormone therapy is a very common treatment for secondary breast cancer and many people take it for a long time. If letrozole stops working, your specialist may prescribe another hormone drug.
7. How it’s taken ?
Consivsure is taken as a tablet once a day, with or without food. It’s best to take it at the same time every day.
If you miss a dose, you don’t need to take an extra dose the next day. The level of drug in your body will remain high enough from the day before.
8. Taking letrozole with other drugs
If you’re taking any other prescribed or over-the-counter medicines, check with your treatment team or pharmacist if you can take these with letrozole.
Do not take other drugs containing oestrogen, such as hormone replacement therapy (HRT), while you’re taking letrozole as this may interfere with its effectiveness.
Talk to your specialist, pharmacist or GP about any complementary therapies, herbal remedies or supplements you want to use before you start using them.
Last reviewed: February 2019
Next planned review begins 2021

CHESTCAREPLUS ChestCare Plus for productive and non-productive cough

  • 124 Patients

Composition of Chestcare Plus

Chestcare Plus

CHESTCARE Terbutaline 1.25 mg, Ambroxol 15 mg, Guaiphenesin 50 mg, Cetrazine 2.5 mg, in Mentholated base q.s.

  • 124 Patients

Composition of Chestcare

Chest Care
Terbutaline 1.25 mg, Ambroxol 15 mg, Guaiphenesin 50 mg, Cetrazine 2.5 mg, in Mentholated base q.s.
Terbutaline used to prevent and treat wheezing, shortness of breath, and chest tightness caused by asthma, chronic bronchitis, and emphysema.
Ambroxol Mucolytic and Mucokinetic
Guaiphenesin is expectorant helps losen congestion in chest and throat, making it easier to cough through mouth.
Cetrazine is antihistaminic also stops itching, water eyes, running nose, treat cold, allergy, etc.
Menthol soothes irritated throat.

Install HB 5ml containing Iron Sucrose, 5 ml Injection

  • 124 Patients

IV iron supplement and oral phosphate binder
Used IV for the treatment of iron deficiency anemia in patients with chronic kidney disease and orally for control of serum phosphorus levels in patients with chronic kidney disease on dialysis Can cause serious, even fatal, hypersensitivity reactions when administered IV; although less likely to cause hypersensitivity than iron dextran, facilities for cardiopulmonary resuscitation must be available during dosing For the treatment of iron-deficiency anemia in patients with chronic kidney disease.
NOTE: A test dose is not required, but has been used at the physician's discretion in 1 of 3 clinical U.S. premarketing trials of hemodialysis patients. In another clinical study, 131 patients received a 50 mg (2.5 mL) test dose of iron sucrose, sucroferric oxyhydroxide diluted in 50 mL of 0.9% Sodium Chloride Injection administered IV over 3 to 10 minutes.
In patients with hemodialysis dependent-chronic kidney disease.
Intravenous dosage
100 mg elemental iron IV. Administer undiluted by slow IV injection over 2 to 5 minutes or diluted in up to 100 mL of 0.9% Sodium Chloride Injection over at least 15 minutes, per consecutive hemodialysis session. Administer early during the dialysis session (generally within the first hour). The usual total treatment course is 1,000 mg elemental iron. Treatment may be repeated if iron deficiency recurs.
Children and Adolescents 2 to 17 years
Dosing for iron replacement treatment in pediatric patients is not established. For iron maintenance treatment, 0.5 mg/kg/dose IV every 2 weeks (Max: 100 mg/dose) for 12 weeks. Administer by slow IV injection (undiluted) over 5 minutes or diluted in 0.9% Sodium Chloride InjectionDosage & Indications
For the treatment of iron-deficiency anemia in patients with chronic kidney disease.
In patients with non-dialysis dependent-chronic kidney disease.
Intravenous dosage
200 mg elemental iron IV. Administer undiluted by slow IV injection over 2 to 5 minutes or diluted in up to 100 mL of 0.9% Sodium Chloride Injection over 15 minutes. Administer on 5 different occasions within a 14-day period. The total cumulative dose administered is 1,000 mg. Treatment may be repeated if iron deficiency recurs. There is limited experience with 500 mg of elemental iron diluted in up to 250 mL of 0.9% Sodium Chloride Injection, given as an IV infusion over 3.5 to 4 hours on day 1 and day 14. In addition, in 107 chronic kidney disease patients, 500 mg of elemental iron has been administered over 3 hours on 2 consecutive days. Two patients experienced drug-related adverse events; 1 patient experienced first-dose epigastric discomfort, nausea, vomiting, and lightheadedness and did not receive further doses, and 1 patient experienced abdominal cramps and moderate nausea lasting 3 days after completing the entire dosage regimen.

Pregnancy and Lactation
Fetal adverse reactions, including fetal bradycardia, have been associated with maternal hypersensitivity reactions, especially during the second and third trimester of pregnancy. Data with intravenous iron sucrose use during human pregnancy have not shown adverse maternal or fetal outcomes; however, reports of intravenous iron sucrose use in pregnant women during the first trimester are insufficient to assess the risk of major birth defects or miscarriage. Treat iron deficiency anemia during pregnancy because there are risks to the mother and fetus associated with untreated iron deficiency anemia during pregnancy.There are no adequate and well-controlled studies of oral sucroferric oxyhydroxide use in pregnant women; however, animal studies have not shown any evidence of impaired fertility or fetal harm at doses up to 16 and 4 times, respectively, the human maximum recommended clinical dose. Sucroferric oxyhydroxide is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug.
Iron sucrose is present in human milk, and available data after exposure to 100 to 300 mg of intravenous iron sucrose have not reported adverse reactions in breast-fed infants. Limited data indicate iron found in breast milk is not increased after intravenous administration of iron sucrose. There are no data on the effects of iron sucrose on milk production. Consider the developmental and health benefits of breast-feeding along with the mother's clinical need for intravenous iron sucrose and any potential adverse effects on the breast-fed infant from intravenous iron sucrose or the underlying maternal condition. Monitor breastfed infants exposed to intravenous iron sucrose for gastrointestinal toxicity (i.e., constipation, diarrhea).Sucroferric oxyhydroxide is not absorbed systemically following oral administration and breast-feeding is not expected to result in exposure of the child to sucroferric oxyhydroxide.

OSTONEURON-B12 B-Complex with Calcium. Vitamin D3 (Cholecalciferol I.P) + Vitamin B12 I.P. 2.5mcg + Calcium Phosphate eqv. to elemental Calcium 82 mg in a falvoured syrupy base.

  • 124 Patients

OSTONEURON-B12 Suspension for kids
Growing child requires calcium to help build strong bones. Ostoneuron-B12 gives growing child calcium,phosphorous, minerals which are the building blocks of bones. Ostoneuron-B12 helps build strong bones.

Safecilin Sultamicillin Tosylate 375 mg Tabs

  • 124 Patients

Molecule Description>
Sultamicillin belongs to the class of Beta-Lactam antibiotics. It is used in the treatment of a wide range of bacterial infections.
Medicines containing Sultamicillin.
Uses of Sultamicillin
Skin and soft tissue infections (bacterial infections)
Urinary tract infections
Female genital infections (gonorrhoea)
Ear infections
Respiratory tract infections
Infections of nose, sinuses and throat
Contraindications of Sultamicillin When should one not use Sultamicillin
Do not take this medicine if you have an allergy to this medicine, any other Beta-Lactam antibiotic or liver disease such as hepatitis.
Side effects of Sultamicillin
Common side effects of this drug are:
Allergic symptoms - itching, hives, rash, and swelling of lips, face, throat, etc.
Precautions and Warnings of Sultamicillin
Q:Can I take Sultamicillin during pregnancy?
A:Limited information is available about its safety in pregnancy. Hence do not take this medicine unless considered essential by your physician.
Breast Feeding
Q:Can I take Sultamicillin while breastfeeding?
A:A small amount of this medicine passes into human breast milk. Watch for any symptoms like skin rash, diarrhea or vomiting to a newborn baby. This medicine is not recommended unless considered essential by your physician. Driving
Q:Can I drive if I have consumed Sultamicillin?
A:If you feel unstable after taking this medicine, you should avoid driving.
Other General Warnings
Talk to your doctor if You experience an allergy to any medicine like skin reactions
You have liver or kidney disease
Mode of Action of Sultamicillin
How Does It Work?

Sultamicillin interrupts bacterial cell wall synthesis, which is the protective covering of bacteria. This leads to death of bacterial cells, thereby offering effective infection control.
Interactions of Sultamicillin
Interactions with other medicines
Concurrent use with Warfarin increases the risk of bleeding
Concurrent use with Methotrexate increases toxicity
It decreases the efficacy of estrogen-containing oral contraceptives
Excretion of this medicine is reduced when used with Probenecid. This leads to higher efficacy
This medicine may reduce the effectiveness of live vaccines
Inform your doctor regarding all the medications that you are following
Interactions with food items
No specific interactions with food have been reported yet.
Dietary Restrictions of Sultamicillin
No information is available on dietary restrictions while you are taking Sultamicillin, consult your doctor or pharmacist for further information.
Dosage of Sultamicillin
If you think you have taken an overdose of Sultamicillin, contact your doctor immediately or visit the nearest hospital.
Missed a Dose
Take the missed dose as soon as you remember. If the time for the next dose is near, do not take a double dose if you have missed the dose.
Frequently Asked Questions (FAQs)
Q: What should I discuss with my healthcare expert before taking Sultamicillin?
Tell your doctor if you have-
Allergy to this medicine or any other beta-lactam antibiotic
Liver disease such as hepatitis
Serious kidney disease
Any other medicine that you may be taking already
Q: What precautions must I take while on the medication of Sultamicillin?
A: It decreases the efficacy of estrogen-containing oral contraceptives. Talk to your doctor about additional methods of contraception that you will need to follow.

Based on 4 reviews
5 stars
4 stars
3 stars
2 stars
1 stars